Tuesday, July 06, 2010 9:40:39 AM
http://ih.advfn.com/p.php?pid=nmona&article=43494887&symbol=CPHI
China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceutical company in China, today announced that the Company's Chief Financial Officer, Mr. Frank Waung, has been invited by Global Hunter Securities to present at the Global Hunter Securities ("GHS") China Conference.
The GHS China Conference will be held on July 11 - 13, 2010 at the St. Regis Hotel in San Francisco. Mr. Frank Waung is scheduled to make a presentation at 3 P.M. PT on Monday, July 12, 2010 and will be available to meet with investors throughout the conference.
For further details, please contact your respective institutional sales representative.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across 30 provinces, municipalities and autonomous regions. The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
For more information, please contact:
China Pharma Holdings, Inc.
Tel: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
CCG Investor Relations
Vivian Chen, Sr. Market Intelligence Exec.
Tel: +1-646-701-7445 (New York)
Email: vivian.chen@ccgir.com
SOURCE China Pharma Holdings, Inc.
Recent CPHI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:05:47 PM
- China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split • PR Newswire (US) • 02/23/2024 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/15/2024 05:15:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:11 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 09:16:44 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/26/2024 10:04:49 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 09:05:53 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/12/2024 07:42:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:05:21 PM
- China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device • PR Newswire (US) • 11/29/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:05:58 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2023 09:05:29 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/27/2023 08:06:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 08:06:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:05:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 07:40:13 PM
- China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs • PR Newswire (US) • 08/09/2023 12:30:00 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM